Keyword: Watson Pharmaceuticals
Plant Construction & Process Technology
25.09.2012
- Pharmaceuticals - Of the many challenges inherent with biosimilar development, the inability to predict market expectations may top the list for decision makers. While uncertainty...
Plant Construction & Process Technology
25.09.2012
- Market Transition - When we think about the patent cliff, an image along the lines of a massive waterfall, with companies' revenues in free fall comes to mind. What we usually...
News
15.08.2012
- Generic drugmaker Watson Pharmaceuticals sued the U.S. Food and Drug Administration, challenging a ruling against Watson's generic version of a big-selling diabetes drug, Actos...
News
04.08.2012
- A divided federal appeals court overturned an order in favor of Momenta Pharmaceuticals that had blocked Watson Pharmaceuticals from selling a generic version of the blood-thinning...
News
21.07.2012
- Aggressive consolidation among U.S. and European generic drugmakers is putting pressure on smaller competitors in the industry, whose best hope of surviving a brewing price war may...
News
25.06.2012
- U.S. regulators have ruled against Shire in a battle over generic copies of its hyperactivity drug Adderall XR, approving a cut-price version of the medicine from Actavis, which is...
News
12.04.2012
- Watson Pharmaceuticals is on track to announce a deal to buy Actavis for around $6 billion by the end of April, creating one of the world's biggest producers of generic drugs...
News
22.03.2012
- Watson Pharmaceuticals Inc is close to buying Swiss-based Actavis for around $7 billion, marking the latest deal between generics companies racing to achieve economies of scale...
